Stockysis — AI-Powered Stock News & Sentiment Analysis

Roth Capital Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $31

Benzinga Newsdesk www.benzinga.com Neutral 60.1%

Neg 0% Neu 60.1% Pos 0%

Roth Capital analyst Adam Walsh initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy rating and announces Price Target of $31.

Comments

No comments yet. Be the first!